Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
2期
进行中（已停止招募）
NCT03141359
| 适应症 | Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Wake Forest University Health Sciences |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 61 人 |
|---|
| 干预（药物） | SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide |
|---|
| 开始日期 | 2017年5月12日 |
|---|
| 完成日期 | 2023年7月12日 |
|---|
| 结果公布日 | 2024年8月29日 |
|---|
摘要
This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation with or without consolidation chemotherapy. A total of 60 subjects will be enrolled to this study over a 4 year accrual period.
Number of Participants Progression Free and Surviving at 12 Months
From date of treatment start to date of progression or death, or censored at 12 months, whichever occurred first. · Participants
| SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy | 37 Participants |
|---|
| p-value | .388 |
|---|
| Rate | 0.627 (95% CI 0.492–0.750) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。